The development of new antiretroviral agents may improve survival of HIV-infected individuals, and therefore chronic viral hepatitis may become more relevant in these patients. The presence of GBV-C/HGV and hepatitis C virus (HCV) RNA were investigated by reverse transcriptasenested polymerase chain
Interferon-α therapy in patients dually infected with hepatitis C virus and GB virus C/hepatitis G virus — virological response of HGV and pretreatment HGV viremia level
✍ Scribed by Etsuro Orito; Masashi Mizokami; Kiyomi Yasuda; Kanji Sugihara; Makoto Nakamura; Motokazu Mukaide; Ken-Ichi Ohba; Tatsunori Nakano; Takanobu Kato; Yutaka Kondo; Takashi Kumada; Ryuzo Ueda; Shiro Iino
- Book ID
- 118567569
- Publisher
- Elsevier Science
- Year
- 1997
- Tongue
- English
- Weight
- 695 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0168-8278
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
We compared characteristics of patients with GB virus C/hepatitis G virus (GBV-C/HGV) RNA to those of patients with GBV-C/HGV E2-antibody. GBV-C/HGV RNA and GBV-C/HGV antibody were assayed in 83 persons with hemophilia using a reverse transcription-polymerase chain reaction and an enzyme-linked immu
Of 74 patients who were infected with hepatitis C virus (HCV) and received interferon, 12 (16%) were positive for RNA of GB virus C (GBV-C). RNA of GBV-C was determined in sera from the co-infected patients retrospectively, and the effect of interferon on GBV-C was compared with that on HCV in them.